Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Spinner Technologies is an Australian biotechnology company that specializes in the development of advanced 3D cell culture platforms. The company's flagship technology, the Spinner platform, is designed to enable the high-throughput production of uniform 3D cell models, such as spheroids and organoids, which are critical for drug discovery and regenerative medicine. By providing a more physiologically relevant environment than traditional 2D cultures, Spinner's technology helps researchers better predict human responses to new therapeutics. In 2021, the company was acquired by Sartorius, a leading international partner of life science research and the biopharmaceutical industry, to enhance their portfolio in cell culture and cell therapy applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Spinner Technologies.